Delcath Systems (NSDQ:DCTH) registered a $100 million offering with the SEC this week to support the development of its system designed to administer high-dose chemotherapy to the liver.
The company’s product, melphalan hydrochloride for injection for use with the Delcath hepatic delivery system, won CE Mark clearance in Europe in 2012 and is under consideration by the FDA in the U.S.
Get the full story at our sister site, Drug Delivery Business News.
The post Delcath registers $100m offering appeared first on MassDevice.